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ABSTRACT
Background
General practitioners (GPs) encounter patients who 
have suffered a fracture or are at an increased risk. 
Fragility fractures cost Europe 32 billion Euros per 
year. Recognizing this challenge and understanding 
its management allows GPs to engage in primary and 
secondary prevention of fragility fractures.
Aim
To illustrate lifestyle and pharmacological management 
options offered by a general practitioner to an adult at 
increased risk of fractures or low bone mineral density 
(BMD).	 The	National	Osteoporosis	Guideline	Group	
(NOGG, 2016), World Health Organisation (WHO), 
International Osteoporosis Foundation (IOF, 2012), 
Kidney Disease Improving Global Outcomes (KDIGO, 
2009), Scottish Intercollegiate Guidelines Network 
(SIGN) and National Institute for Health and Care 
Excellence (NICE) management guidelines are discussed 
in this regard.
Objectives
•	 To provide key definitions in the management of 
osteoporosis.
•	 To	identify	groups	at	risk	of	developing	low	BMD,	
vitamin D deficiency and fragility fractures.
•	 To illustrate the current management options for 
an adult at increased risk of fractures or low bone 
mass by a general practitioner.
•	 To discuss current methods of investigation and 
measurement	of	low	BMD,	fracture	risk	assessment	
and vitamin D deficiency.
•	 To address dietary requirements of calcium and 
vitamin D and local formulations available.
Method
A literature search was conducted using Pubmed and 
Google search engines. Keywords included: osteoporosis; 
low bone mineral density; vitamin D; fragility fracture; 
postmenopausal. The NOGG (2016), WHO, IOF (2012), 
KDIGO (2009), SIGN and NICE management guidelines 
were included directly. Treatments ranging from fall 
prevention, dietary modification, anti-resorptive therapy 
and tailoring in subgroups were reviewed.
Conclusion
Guidelines can close the gap between physicians in 
primary and secondary care, institutions and private 
practice providing a multifaceted approach for the proper 
identification, prevention and management of fragility 
fractures.
Key words
Osteoporosis, risk assessment, bone density conservation 
agents.
INTRODUCTION
General practitioners (GPs) encounter patients who have 
suffered a fracture or are at an increased risk. Post-fracture 
management models of care (IOF, 2012) have been 
developed to better identify those at risk. Nine million 
fragility fractures occur annually globally. Thirty-two 
billion Euros per year are spent in Europe. Recognising 
this challenge and understanding its management 
allows GPs to engage patients at primary and secondary 
prevention before a fracture career sets in.
Aim
To illustrate the management options that could 
be offered by a general practitioner for an adult at 
increased risk of fractures or low bone mineral density. 
The NOGG - National Osteoporosis Guideline Group 
(2016), WHO – World Health Organisation, IOF - 
International Osteoporosis Foundation (2012), KDIGO 
- Kidney Disease Improving Global Outcomes (2009), 
SIGN - Scottish Intercollegiate Guidelines Network, 
and NICE - National Institute for Health and Care 
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Excellence management guidelines are discussed in this 
regard. Treatments ranging from fall prevention, dietary 
modification, anti-resorptive therapy and tailoring of 
treatment in subgroups were reviewed.
Objectives
•	 To provide key definitions in the management of 
osteoporosis, fracture prevention and vitamin D 
physiology.
•	 To identify those at risk of developing osteoporosis 
and vitamin D deficiency.
•	 To discuss methods of measurement and 
investigation	of	low	bone	mineral	density	(BMD),	
fracture risk assessment and vitamin D deficiency.
•	 To address the dietary requirements of calcium and 
vitamin D and local formulations available.
•	 To discuss the recommended treatments for low 
bone mass, osteoporosis and persons at high risk 
of fragility fractures.
METHOD
A literature search was conducted using Pubmed and 
Google search engines. Keywords in searches included: 
osteoporosis; low bone mass; vitamin D; fragility fracture; 
postmenopausal. Sources directly included were the 
Kidney Disease Improving Global Outcomes (KDIGO, 
2009), International Osteoporosis Foundation (IOF, 
2012), National Osteoporosis Society (England) (NOS, 
2013), International Society for Clinical Densitometry 
(ISCD, 2015), the National Osteoporosis Guideline 
Group (UK) (NOGG, 2016), the Scottish Intercollegiate 
Guidelines Network (SIGN), the National Institute for 
Health and Care Excellence (NICE, UK) and the 71st 
edition	of	the	British	National	Formulary.
Ethical aspects
Photos included in this article of patients at Karen Grech 
Hospital were attained after permission was granted by 
the hospital’s data protection officer and chief executive 
officer, and written informed consent was obtained from 
the patients.
RESULTS
Definition and diagnosis of osteoporosis
In 1994 the World Health Organization (cited by NOGG, 
2016) described osteoporosis as a ‘progressive systemic 
skeletal disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue, with a 
consequent increase in bone fragility and susceptibility 
to fracture’. ‘Osteoporosis’ is defined operationally as 
a	 value	 for	BMD	 that	 is	 2.5	 standard	deviations	 (SD)	
or less below the young adult mean value (T-score ≤ 
–2.5 SD). Lorentzon and Cummings (2015) however 
concluded that no perfect definition yet exists that can 
ascribe to the properties of fragile bone measured in 
terms of bone strength, risk factors and prior fractures. 
‘Severe osteoporosis’ refers to the above and an additional 
Figure 1: Fall management exercise.
Figure 2: Lower limb proprioception exercise.
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documented fragility fracture. A higher threshold 
describes ‘low bone mass’ as a T-score that lies between 
–1 and –2.5 SD (NOGG, 2016).
Assessment of fracture risk
The NOGG (2016) and ISCD (2015) recommend 
the use of FRAX® as the preferred fracture risk score 
assessment tool in calculating the 10-year probability 
of major osteoporotic and hip fractures. FRAX® was 
modelled on population-based cohorts where the 
femoral	 neck	 BMD	was	 used.	 The	 latter	 is	 therefore	
preferred when calculating risk, especially in the elderly 
where arthrosis and arthritis are established in the spine 
(University of Sheffield, 2011). Outcomes and follow 
up of treatment favour scores of the lumbar spine. The 
lower of the two T-scores should be used in diagnosing 
osteoporosis. Z-scores should be used in adults under 
50 years of age with values < -2 being below the 
expected range (ISCD, 2015). 
Strategies in the prevention of osteoporosis
The NOGG (2016) endorses a group of strategies in 
high-risk groups to prevent fragility fractures globally. 
The main message is that of increasing mobility and 
calcium intake, stopping smoking, reducing alcohol 
consumption (less than 3 units a day), undertaking fall 
prevention programmes, weight bearing and balance 
exercises (Figures 1-5). Other indirect interventions, 
such as the correction of visual acuity and the 
adjustment of medication that could affect alertness, 
have also been promoted.
Vitamin D
A serum level of 25-hydroxyvitamin D (25-(OH)D) 
(calcifediol) below 25nmol/L (i.e. <10ng/mL) is considered 
as ‘vitamin D deficiency’ and may lead to mineralization 
defects. ‘Vitamin D insufficiency’ occurs between 25nmol/L 
and 50nmol/L (i.e. <20ng/mL) and can lead to increased 
bone turnover and parathyroid hormone anomalies. The 
NOS (2013) states that half the patients with levels of 
vitamin D between 20-30nmol/L are vitamin D sufficient 
but all those above 50nmol/L are practically sufficient. The 
sufficiency of vitamin D on individuals varies according 
to the response on parathyroid hormone. Adverse effects 
may occur with levels above 125nmol/L and annual high 
dose vitamin D (500,000 IU) is associated with greater 
incidences of falls and fractures (NOGG, 2016). On the 
other hand Rizzoli et al. (2013) as part of the European 
Society for Clinical and Economic Aspects of Osteoporosis, 
Osteoarthritis and Musculoskeletal diseases and the NOS 
(2013) recommend vitamin D levels to be at least above 
60nmol/L in the general population and ideally 75nmol/L 
in frail elderly patients who are at risk of falls or fracture for 
skeletal and extra-skeletal benefits.
Ross et al. (2013) recommend an intake of 800IU 
of vitamin D daily. Simple deficiency can be treated 
by administering 400 units (10ug) of ergocalciferol or 
colecalciferol twice daily. In those with little exposure 
to sunlight or have a limited diet, 800 units is 
recommended. Higher doses of 40,000 units (1mg) daily 
are appropriate in intestinal malabsorption and chronic 
liver disease states. Severe deficiency (<8ng/ml) may even 
require 50,000 units daily for one to three weeks (JFC, 
2016). In cases of mild to severe deficiency (8-25ng/ml) 
50,000 IU weekly for 8 weeks can be offered, followed by 
a maintenance dose of 800-2000 IU vitamin D orally daily 
for one month (NOS, 2013; Płudowski, et al., 2013). 
Serum calcium must be checked one month after the 
last loading dose to unmask hyperparathyroid states, and 
vitamin D measured 3-6 months after treatment has been 
terminated as levels reach a steady state after this period 
(NOS, 2013). Routine monitoring is not recommended 
but may be appropriate in patients with malabsorption 
syndromes and poor compliance (Kennel, Drake and 
Hurley, 2010; Ross, et al., 2011).
NICE (2016) determined that persons at risk of 
vitamin D deficiency include:
Figure 3: Stepping exercise.
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of bone morphology which is confirmed by bone biopsy 
in those with chronic kidney disease (KDIGO, 2009a). 
Alfacalcidol, a hydroxylated form of vitamin D, can be 
used as an alternative. It will not influence 25-(OH)D 
plasma concentrations and cannot be directly measured. 
Alfacalcidol can be prescribed at 1ug daily in adults and 
0.5ug daily in the elderly. Calcium and phosphate levels 
serve as rough indicators to whether one is overtreating 
(JFC, 2016).
Figure 4: Parallel bars for walking and gait training.
Table 1: Local preparations of combined calcium and vitamin D
Formulation
Calcium salt 
per single unit
Percentage 
of elemental 
calcium per salt
Elemental 
calcium 
per tablet
Cholecalciferol Comments 
Tablet 1250mg calcium 
carbonate 
40% 500mg 400IU 
Tablet Not available. 400mg 400IU 
Magnesium, zinc, 
copper, manganese, 
selenium and boron 
included 
Effervescent 
tablet
Not available. 400mg 100IU 
Syrup Not available. 600mg per 
20ml
300IU per 20ml
Tablet 300mg calcium 
lactate 
13% 39mg 25 tablets daily would be recommended 
for adequate elemental calcium intake. 
Tablet 600mg calcium 
hydrogen 
phosphate
23% 138mg 500IU 4-5 tablets needed to attain the 
recommended dose of elemental 
calcium; however the intake of vitamin D 
would be high.
Sources: Globalrph, 1993; Ross, et al., 2011.
•	 infants and children aged under 5 years;
•	 pregnant and breastfeeding women, particularly 
teenagers and young women;
•	 people over 65 of age;
•	 persons with little or no exposure to the sun, 
for example persons who remain indoors for 
long periods or have a large surface of their body 
covered due to cultural reasons;
•	 people with darker skin.
Vitamin D in Chronic Kidney Disease
As Figure 6 demonstrates, renal function plays a part 
in the conversion of 25-(OH)D to the active form 
1,25-(OH)2D. This ability diminishes at an estimated 
glomerular filtration rate (eGFR) <30ml/min/1.73m2 and 
leads to impaired hydroxylation of vitamin D. Secondary 
effects include: raised parathyroid hormone (PTH) 
levels, reduced intestinal calcium absorption, reduced 
phosphaturia, and reduced calcium urinary reabsorption. 
PTH, calcium and phosphate should be measured to 
reflect this deficiency. The cardiovascular, biochemical, 
endocrine and bone mineral disorders that develop 
secondary to renal impairment were coined ‘Chronic 
Kidney	Disease-Mineral	 and	 Bone	Disorder’.	 ‘Renal	
osteodystrophy’ is restricted to describing an alteration 
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Calcium
The Institute of Medicine (IOM, US) Committee to 
Review Dietary Reference Intakes for Vitamin D and 
Calcium recommends 1gr. of elemental calcium per 
day after meals (IOM, 2011). The low pH improves 
absorption and halving the dose into a twice daily 
regimen prevents saturation of the gastrointestinal tract. 
Thiazide diurectics, lithium and low sodium diets will 
enhance renal excretion of calcium and losses (WHO, 
2004; Kennel, Drake and Hurley, 2010; SIGN, 2015).
Calcium supplements contain different amounts of 
elemental calcium. The supplements facts panel of a product 
can be used to calculate the amount of elemental calcium 
available. There are online calculators that can determine 
this (Institute of Genetics and Molecular Medicine, 2016). 
Table 1 presents local combined preparations of calcium and 
vitamin D and the percentage of elemental calcium per salt. 
Identifying cases of osteoporosis 
and low bone mineral density
A study by Gourlay et al. (2012) followed the time 
needed	 to	 reach	 a	 T-score	 of	 -2.5	 on	BMD	 in	 almost	
6,000 predominantly white women over 65 years of age, 
who were ambulatory and did not suffer a prior hip or 
vertebral fracture. The study included co-variates for age, 
smoking, glucocorticoid use, oestrogen use and self-reported 
rheumatoid arthritis. The outcomes for recommended follow 
up DXA scanning for osteopenia was shown to depend on 
the severity as illustrated in Table 2. The global risk still needs 
to be considered when following up patients, as well as the 
onset of new diseases such as diabetes, immobility, etc. This 
study was criticized on these grounds as risk for fracture is 
not attributable to T-scores alone. Apart from this a clinically 
significant	change	in	BMD	was	appreciable	after	a	minimum	
of 2 years according to the National Clinical Guideline Centre 
(2012). Women were not given lifestyle advice or started on 
supplementation in the study, which could influence the rate 
of	deterioration	in	BMD.
NOGG (2016) identifies the secondary causes of 
osteoporosis as:
•	 chronic obstructive pulmonary disease,
•	 rheumatoid arthritis,
•	 untreated hypogonadism in men and women,
•	 prolonged immobility,
•	 organ transplantation,
•	 type I diabetes,
•	 hyperthyroidism,
•	 gastrointestinal disease,
•	 chronic liver disease.
Investigations to exclude secondary sources may be 
indicated were appropriate. Serum total calcium, total 
protein and albumin for a corrected calcium level (or ionized 
calcium), phosphate, alkaline phosphatase levels for Paget’s 
disease, creatinine for eGFR and PTH are to be assessed 
if calcium levels are deranged. A full blood panel and 
erythrocyte sedimentation rate would screen for inflammatory 
processes while serum protein electrophoresis would assess 
for free light chains indicative of multiple myeloma. Thyroid 
function tests are advised in suspected thyrotoxicosis, serum 
testosterone for hypogonadism, coeliac serology for related 
malabsorption and an overnight dexamethasone suppression 
test to exclude Cushing’s disease (Lee and Vasikaran, 2012).
Types of fractures
The NOGG (2016) defines the different types of clinically 
relevant fractures. A major osteoporotic fracture is a clinical 
spine, hip, forearm or humerus fracture; however multiple 
major fractures carry a higher risk than the adding up 
of each individual risk. Vertebral fractures carry a two-
fold higher risk than other types of fractures. A fragility 
fracture follows a fall from standing height or less. Fragility 
fractures may be consequential to osteoporosis or other 
more serious conditions affecting bone such as metastatic 
bone cancer or myeloma.
Pharmacological interventions
in osteoporosis
There are conflicting recommendations when it comes to 
starting treatments. The NOGG (2016) deemed treatment 
be considered in those above the intervention threshold Figure 5: Training stairs used for lower body
co-ordination and balance.
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calculated by FRAX®	and	started	without	prior	BMD	in:
•	 postmenopausal (PMP) women who have had a 
previous fragility fracture,
•	 people over 70 years of age who are taking large 
doses of oral corticosteroids,
•	 PMP women and men under 50 years of age 
who have had an osteoporotic fracture (specialist 
management is recommended in this group).
SIGN (2015) is more cautious and recommends 
measurements	 of	 BMD	 by	DXA	 in	 those	 above	 the	
intervention threshold, with pharmacotherapy started 
in those with T-scores < -2.5. The group goes on to 
comment that therapy can be commenced in patients 
with prevalent vertebral fractures without undertaking 
BMD	measurements	if	these	are	felt	to	be	inappropriate	or	
impractical, implying that skeletal imaging be performed 
as part of screening in certain cases. NICE does not 
comment with regards to the grey area incorporating 
those who are above the intervention threshold but have 
a femoral neck T-score > -2.5. Perhaps the intervention 
here lies in the global initiatives recommended by 
NOGG (2016) as the effect of alendronic acid, studied 
by Cummings et al. (1998) in the FITS trial, showed only 
a statistically-significant reduction in clinical fractures in 
women with a femoral neck T-score < - 2.5 after 4 years. 
Women treated with higher T-scores did not show an 
improvement in fracture rates.
Patients treated with anti-resorptive therapy will have 
a	demonstrable	improvement	in	BMD	after	three	years	
of treatment and for this reason guidelines recommend 
repeat	 BMD	 testing	 after	 this	 period	 and	 not	 sooner	
as the within-person variations differ widely with DXA 
measurement after just one year of treatment (Sharma 
and Stevermer, 2009; Ott, 2013; Doshi, et al., 2016).
The preferred first line treatments offered by NICE are 
bisphosphonates. They act by inhibiting bone resorption 
by binding to hydroxyapetite crystals. Indications such 
as glucocorticoid induced osteoporosis or vertebral 
fractures make certain interventions more appealing 
than others (Table 3). To postmenopausal women who 
are unable to comply with the special instructions, have 
a contraindication or are intolerant to certain treatments, 
NICE	 gives	 the	 variables	 (e.g.	 BMD	 thresholds)	 and	
clinical scenarios against which other treatment options 
can be weighed.
Denosumab is a monoclonal antibody that inhibits 
osteoclast formation, function and survival. Its use is 
Figure 6: Metabolism of 
vitamin D (Hollis, 2006). 
[UVB	–	ultraviolet	light	B;	
PTH – parathyroid hormone]
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Table 2: Time to develop osteoporosis in low bone mass in white 
women over 65 years of age, who were ambulatory and did not suffer 
a prior hip or vertebral fracture
Severity T-Score Ranges Time (years)
Mild -1.00 to -1.49 15
Moderate -1.5 to -2 5
Severe -2 to -2.49 1
Source: Gourlay et al. (2012).
recommended with caution in those with an eGFR < 
30ml/min/1.73m2 (NOGG, 2016) and is second-line to 
cases where there was an insufficient response, along with 
zoledronic acid. Strontium ranelate works by stimulating 
bone formation and reducing resorption. Raloxifene acts 
as a selective oestrogen receptor modulator that inhibits 
bone resorption and is only indicated in the secondary 
prevention of osteoporosis (JFC, 2016) (Table 3).
After three to five years of treatment, NOGG (2016) 
asks	physicians	 to	 review	BMD	measurements	 and	 to	
offer patients to stop treatment if acceptable T-scores have 
been reached and no fractures have occurred. Follow up 
DXA scanning should take place after two years (three 
years in the case of zoledronic acid) and after a new 
fracture regardless of when this occurs.
Interventions in chronic kidney disease
Chronic kidney disease (CKD) stages 1-2 and stage 3 with 
a normal PTH range are recommended management as for 
the general population for osteoporosis and/or high risk 
of fracture. With abnormal biochemical markers at CKD 
stage 3 one should consider the degree and reversibility 
of the biochemical anomalies and a bone biopsy. In CKD 
stages 4-5D having biochemical anomalies of chronic 
kidney	disease	-mineral	and	bone	disorder	(CKD-MDB),	
low	BMD	or	fragility	fractures,	a	bone	biopsy	is	suggested	
prior to therapy with anti-resorptive agents (KDIGO, 
2009b). Table 4 illustrates the frequency of measurements 
of bone turnover markers.
Treatment issues and counselling
Patients should be counselled about the following issues 
before and during anti-resorptive treatment:
•	 dental checkups should take place prior to treatment 
and on a regular basis. Invasive dental procedures 
should be avoided. Gum swelling and hypermobility 
of the teeth should be immediately reported.
•	 bisphosphonate tablets are to be swallowed 
whole with plenty of plain water only. Their use is 
cautioned or contraindicated in patients with gastric 
or duodenal ulcers, bedridden patients and those 
with eGFR<35ml/min/1.73m2 (NOGG, 2016).
•	 calcium supplements are to be taken at least two 
hours before or after a bisphosphonate and should 
be taken during anti-resorptive treatment along 
with vitamin D.
•	 the length of time one should avoid food before 
and after taking a bisphosphonate should be 
consulted for every product according to the 
dose. Aldendronic acid should be taken 30 
minutes before breakfast on an empty stomach. 
Thirty minutes must elapse before eating or 
taking other medications and lying down after 
taking alendronic acid.
•	 atypical fractures of subtrochanteric and diaphyseal 
regions of the femoral shaft should be reported to 
the prescriber.
•	 it is important to check serum calcium one 
week before and two weeks after administration 
of denosumab and monitor for the presence of 
hypocalcaemia.
•	 patients taking raloxifene should be counselled 
that discontinuation should take place at 
least 72 hours prior to and during prolonged 
immobilization as it confers a greater risk of stroke 
and venous thromboembolic events. It also confers 
a reduction in risk of breast cancer but can also 
procure hot flushes (JFC, 2016).
Bisphosphonates	could	be	continued	indefinitely	in	
high-risk individuals who (NOGG, 2016):
•	 are aged 75 years or more;
•	 have sustained a hip or vertebral fracture;
•	 are taking continuous oral glucocorticoids at a dose 
of ≥ 7.5 mg/day prednisolone or equivalent;
•	 sustain a low trauma fracture during treatment, 
after exclusion of poor adherence to treatment 
(<80%	of	treatment)	and	causes	of	secondary	
osteoporosis have been excluded (in such cases 
treatment should be re-evaluated);
•	 have	a	total	hip	or	femoral	neck	BMD	T-score	≤ 
-2.5 SD.
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Table 3: Recommended anti-resorptive treatments
Choice Drug Indication Duration Frequency Dose 
PMP 
Women
Gluco-
corticoid 
induced
Men
First
Alendronate Yes Yes Yes 5-10 years
daily 10mg
weekly 70mg
Risedronate Yes1 Yes Yes 5-7 years
daily 5mg
weekly 35mg
First /
Second
Zoledronic acid Yes2 Yes Yes 3 years yearly 5mg
Second
Denosumab Yes3 5 years six months 60mg
Teriparatide Yes4 24 months daily 20ug
Third
Strontium ranelate Yes5,6 Yes 10 years daily 2g
Ibandronate Yes 5 years monthly 150mg
Raloxifene Yes Until 50 years of age daily 60mg
Source: NICE, 2008a; NICE, 2008b; JFC, 2016; NOGG, 2016; SIGN, 2015.
(1) Risedronate is recommended as second line in the primary and secondary prevention of osteoporotic risk fractures in patients 
unable to tolerate alendronate against the variables provided by NICE (2008a; 2008b).
(2) Zoledronic acid was shown to improve survival in hip fracture patients unable to tolerate oral osteoporosis treatment and is 
recommended as second line in such cases (SIGN, 2015) or if inadequate response to initial agents.
(3) Denosumab is recommended as third line treatment in the primary and secondary prevention of osteoporotic fractures if 
alendronate and either risedronate or etidronate are not tolerated and against the variables recommended by NICE (2010) or if 
inadequate response to initial agents.
(4) Teriparatide is indicated in severe spinal osteoporosis as second line to alendronate or risedronate.
(5) NICE recommends that raloxifene and strontium ranelate are recommended as alternative treatment options for the secondary 
prevention of osteoporotic fragility fractures in PMP women who are unable to comply with the special instructions for the 
administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate 
and either risedronate or etidronate against the variables recommended by NICE (2008a; 2008b).
(6) Strontium ranelate is recommended as third line to alendronic acid, etidronate and risedronate when it comes to the prevention 
of osteoporotic fragility fractures in PMP women (NICE, 2008a; NICE, 2008b). Strontium ranelate is recommended in severe PMP 
osteoporosis to reduce the risk of vertebral and non-vertebral fractures in women without established cardiovascular disease when 
other treatments are contraindicated (SIGN, 2015).
Table 4: Frequency of measurement per respective bone turnover marker in chronic kidney disease
Stage
eGFR
(ml/min/1.73m2)
Frequency of measurement (months)
Calcium and phosphate Parathyroid hormone Alkaline phosphatase
3 30-59 6-12 According to disease progression
4 15-29 3-6 6-12
121
5 <15 1-3 3-6
1. Stages 4–5D alkaline phosphatase activity measurement: every 12 months, or more frequently in the presence of elevated PTH.
Source: KDIGO, 2009a.
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Glucocorticoid-induced osteoporosis
Steroid doses greater than an equivalent of 7.5mg 
prednisolone daily for more than three months are 
considered significant. Daily doses of prednisolone higher 
or equal to 15mg however should need a higher adjustment 
of fracture probability (NOGG, 2016). Treatment should 
be started at the beginning of steroid therapy in patients 
considered at risk of fracture (JFC, 2016).
Osteoporosis in men and women
Secondary causes are commoner amongst men and will need 
investigation (NOGG, 2016). Hormone replacement therapy 
(HRT) should be offered to women who have experienced 
premature menopause (before 45 years of age) to reduce 
the risk of fragility fractures and for the relief of menopausal 
symptoms. If the main concern is increased fracture risk, 
bisphosphonate therapy should be offered first line. HRT was 
shown to decrease fracture risk but benefits were lost shortly 
after stopping therapy. HRT should be continued up until 50 
years of age and then stopped and the need for continuing 
treatment with an alternative drug considered (JFC, 2016).
DISCUSSION
The different levels of Vitamin D for different ages is still a 
subject of debate. Ultimately the pathophysiology behind 
low bone mineral density reflects our investigation and 
management.
Secondary causes and risk factors should be looked out 
for pending a mandatory dental review along with proper 
counselling if bisphosphonates are considered. T-scores 
measured after a minimum 2 years of treatment with anti-
resorptive agents accompanied by calcium and vitamin 
D supplementation should then be followed up. Earlier 
measurements can deceive GPs into perceiving that no 
improvement	BMD	deterioration	has	occurred	as	within-
person variation confounds measurements. Those with 
an eGFR <30min/1.73m2 should have bisphosphonate 
therapy stopped and be switched to alfacaldidol or another 
suitable	 vitamin	D	alternative.	 For	 those	with	BMD	>	
-2.5 bisphosphonates will not decrease fracture rates and 
prevention lies in managing other risk factors. Patients 
after	a	minimum	three	year	period	with	an	adequate	BMD	
(T-score > -2.5) should be counselled about stopping 
antiresorptive therapy and considered for follow up after 
2 years. At the end of the spectrum recognising fragility 
fractures allows us to treat them as such, irrespective of the 
sex of the patient. Major osteoporotic fractures, especially 
spinal fractures, increase one’s fracture probability further 
and should be accounted for when using prediction tools.
The authors look forward to the identification of 
other risk factors that could have a role in osteoporosis. 
Anti-resorptive treatments are currently limited by gastric 
side-effects and renal impairment. Safer alternatives are 
still needed in these groups.
Limitations
This review does not include the management of secondary 
causes of osteoporosis and younger age groups.
CONCLUSION
Guidelines can close the gap between physicians in 
primary and secondary care, institutions and private 
practice by providing a multifaceted approach for the 
proper identification, prevention and management of 
fragility fractures.
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